Stock Market Reviews

TERN (Terns Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on TERN (Terns Pharmaceuticals, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference
  CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026 Planned milestones include pivotal dose selection, EOP2 regulatory interaction in mid-2026, updated and expanded CARDINAL data by 2H26, and initiation of 2L+ pivotal trial in late 2026/early 2027 TERN-701 was granted U.S. FDA Fast Track designation for the treatment of CML in Q4 2025 Year-end 2025 unaudited cash, cash equivalents and marketable securities of approximately $1.0 billion, expected to pro
  Jan 7, 2026 - $TERN
• Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
  FOSTER CITY, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of January 1, 2026 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made
  Jan 2, 2026 - $TERN
• Tern Pharmaceuticals (TERN) Soars 630% on CML Treatment Best-in-Class Potential
  We recently published 10 Market Stars Behind Millionaire-Making in 2025. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the top performers. Terns Pharmaceuticals climbed by 629.64 percent in 2025, primarily boosted by stellar results from the clinical trial of its therapy candidate for chronic myeloid leukemia (CML), which has the potential to become the best-in-class therapy […]
  Jan 2, 2026 - $TERN
• Jim Cramer Highlights Massive Gains for Terns Pharmaceuticals Shareholders
  Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the stocks Jim Cramer was asked about. Inquiring about the stock, a caller mentioned that they purchased it at approximately $5, and it declined to $2 before surging to around $48 on Friday and then pulling back slightly. Cramer commented: “Man, you just, you know, right now, the […]
  Dec 19, 2025 - $TERN
• Terns Pharmaceuticals (TERN) Climbs 53% on Stellar Leukemia Treatment Trial
  We recently published 10 Stocks Delivering Explosive 18-190% Gains. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the last week’s heavy gainers. Terns Pharmaceuticals soared by 53 percent in just the past five trading days of the week, primarily buoyed by encouraging results from its therapy candidate for chronic myeloid leukemia (CML). In an updated report […]
  Dec 14, 2025 - $TERN
• Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
  FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the closing of its previously announced underwritten public offering of 18,687,500 shares of its common stock, including 2,437,500 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares, at a public offering price of $40.00 per share, before underwriting discounts and comm
  Dec 11, 2025 - $TERN
• Why Terns Pharmaceuticals (TERN) Is Up 54.9% After Upsized $650 Million Equity Raise Following TERN-701 Data
  Terns Pharmaceuticals has completed an upsized US$650 million follow-on equity offering at US$40 per share, alongside a new universal shelf registration, soon after releasing updated Phase 1 CARDINAL trial data for its investigational CML therapy TERN-701 showing high major molecular response rates and encouraging safety. The sequence of raising very large growth capital immediately after presenting TERN-701 data underscores how strongly the company is prioritizing this program’s development...
  Dec 10, 2025 - $TERN
• Terns Pharmaceuticals (TERN): Reassessing Valuation After CARDINAL CML Data Fuels Sharp Share Price Surge
  Terns Pharmaceuticals (TERN) has suddenly landed on many investors radar after reporting encouraging CARDINAL trial data for its CML pill, with major molecular response rates and cancer cell reductions helping drive a sharp move in the stock. See our latest analysis for Terns Pharmaceuticals. That excitement has turbocharged the stock, with the 30 day share price return of 122.65 percent and 90 day share price return of 472.18 percent feeding into a powerful year to date surge of 650.79...
  Dec 10, 2025 - $TERN
• Terns Announces Pricing of Upsized $650 Million Public Offering
  FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the pricing of its upsized underwritten public offering of 16,250,000 shares of its common stock at a public offering price of $40.00 per share, before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable b
  Dec 10, 2025 - $TERN
• Terns (TERN) Hits All-Time High on Stellar Leukemia Treatment Results
  We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the best performers on Monday. Terns soared to a new all-time high on Monday as investors took heart from the encouraging results of its clinical trial to test the efficacy of drug candidate, TERN-701, […]
  Dec 9, 2025 - $TERN